Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of BIIB095 in Healthy Subjects
NCT03454126Phase 1Completed
- Sponsor
- Biogen
- Start
- Mar 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BIIB-095 in neuropathic pain (11 cohorts), sponsored by Biogen. Primary endpoints: Percentage of Participants with Serious Adverse Events up to 59 Days, Percentage of Participants with Adverse Events up to 59 Days and 4 more. Started Mar 2018; status: completed.
02
Drugs
BIIB-095
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT03454126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03454126.